COMPANY PROFILE

Genomtec

Explore full profile

Innovative diagnostic device, based on the amplification and detection of specific DNA and RNA fragments

Wroclaw, PolandFounded 2016Biotech & Life Sciences

Valuation $16M Market cap · 2026

Revenue $5K Latest reported FY

Total funding $10–50M Disclosed equity funding

About Genomtec

Genomtec S.A. is a pioneering startup in the field of molecular diagnostics, focusing on developing innovative, portable testing solutions. The company operates in the global molecular diagnostics market, which has seen significant growth, especially with the impact of the COVID-19 pandemic. Genomtec's primary product offerings include the SARS-CoV-2 Direct RT-LAMP CE IVD Kit and the SARS-CoV-2 RT-LAMP CE IVD Duo Kit. These kits are designed for rapid and accurate detection of the SARS-CoV-2 virus, which causes COVID-19.

Read full description

The company's target clients include healthcare providers, laboratories, and possibly governmental health agencies that require efficient and reliable diagnostic tools. By providing these clients with advanced testing kits, Genomtec helps them deliver timely and accurate diagnoses, which is crucial for effective disease management and control.

Genomtec's business model revolves around the development, production, and sale of its diagnostic kits. The company generates revenue by selling these kits to its clients, who use them for testing and diagnostic purposes. Additionally, the company may also engage in partnerships or collaborations with other entities in the healthcare and diagnostics sectors to expand its market reach and enhance its product offerings.

In summary, Genomtec S.A. is a key player in the molecular diagnostics market, offering cutting-edge testing solutions that cater to the needs of healthcare providers and laboratories. The company's innovative products and strategic business model position it well for continued growth and success in the rapidly evolving diagnostics landscape.

Source: Dealroom company data